Before joining the family business, Giacomo was a consultant with Bain & Co. and Accenture. Since then, he’s expanded the Chiesi Group presence in the US and EU and established a global portfolio and pipelines in rare diseases. Throughout his career, Giacomo has directly structured and executed deals of more than $3B in value, including sell-side to buy-side M&A, in- and out-licensing, and spinouts.

Dr. Freisens is the author and coauthor of several manuscripts published in peer-reviewed journals covering topics related to Gaucher disease and has supported the establishment of international scientific platforms for rare disease experts, including the Gaucher Leadership Forum.

Dr. Freisens completed her medical training at the Medical University in Belgrade and holds ophthalmology specialization from the Moscow Medical University.

Enrico offers extensive expertise in launching and sustaining the growth of therapies in the rare and specialty care disease spaces. As a member of several biotech/RD and orphan drugs associations, Enrico is invested in serving the rare disease community in every way he can.

Diego was the clinical lead with Chiesi Group in the registration of the first stem cell therapy in the EU and led the cross-company team (with uniQure BV) in treating the first patient with commercial gene therapy. Diego was also a serving chairperson of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and is currently serving as board member of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and of the RE(ACT) Discovery Institute Industry Advisory Board.

Before joining Chiesi Global Rare Disease, John was the ApoPharma Director of Commercial Operations for the Americas. John worked for Daiichi Sankyo for 19 years, where he served as the National Director of Oncology and launched Zelboraf^® (vemurafenib). In this role, he also served as a member of the pexidartinib and tivantinib global new product teams. In 1996, John was selected as a “charter member” to launch Camptosar^® (irinotecan) and led commercial teams through multiple mergers and acquisitions.

Prior to joining Chiesi GRD, Larry served as the VP, Global Launch Lead for Rhythm Pharmaceuticals, where he was responsible for leading the launch strategy and developing solutions for physicians, including the creation of a global genetic testing program.  Larry also held leadership roles at Shire, where he led the prelaunch global commercial planning in the disease areas of eosinophilic esophagitis and hereditary angioedema.

Prior to moving into rare diseases, Larry worked at GSK and Merck and held a series of roles of increasing responsibility.  In his last role at GSK, he was the Senior Director of the Pediatric Vaccine Commercial Strategy Team and was responsible for delivering gross annual revenue of greater than $1B.

Stuart has over 20 years of global advocacy experience, including roles as Global Director of Public Affairs & Patient Advocacy for rare blood disorders at Sanofi Genzyme and leading Global Patient Advocacy for Bioverativ Therapeutics’ precommercial rare disease pipeline.

In addition, Stuart is the Cofounder and Director of the Sanfilippo Research Foundation—a nonprofit dedicated to research—in Sanfilippo Syndrome/MPS III, an ultra-rare inherited lysosomal storage disorder that affected his son Benjamin.

Stuart is no stranger to the personal impact rare diseases can have on individuals and their loved ones. That is why he also serves on advisory boards and is an active member of numerous NGO, industry, and governmental rare disease groups and associations.

During his most recent tenure at ApoPharma, Fernando provided consultation on all medical issues including clinical trial strategy decisions for both pre-market and post-market studies in alignment with corporate policies and regulatory requirements.

Fernando received the 2017 Humanitarian of the Year Award from Cooley’s Anemia Foundation and the 2018 United Kingdom Thalassaemia Society Award for his work on the development of a treatment of iron overload in patients with thalassemia.

Prior to his experience in GRD, Davide worked for nearly five years in the International Market Development Division of Chiesi, in which he supported area managers and business operation in evaluations, forecasts, analysis, and plans. Davide also brings five years of experience in the FMCG sector, where he worked as a business analyst for Soremartec (Ferrero Group), working on the evaluation of new products under development and their acceptability and forecasted performance at the global level.

During her tenure as Finance Business Partner at Sanofi-Genzyme Italy & Malta, Gaia supported the leadership team in managing financing and operations including several product launches within rare and specialty care diseases.